Literature DB >> 29112457

FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.

Indira M Elangovan1, Michelle Vaz2, Chandramohan R Tamatam1, Haranatha R Potteti1, Narsa M Reddy1, Sekhar P Reddy1.   

Abstract

The FOSL1/AP-1 transcription factor regulates gene expression, thereby controlling various pathophysiological processes. It is a major effector of RAS-ERK1/2 signaling and is activated in human lung epithelia by tumorigenic stimuli. Recent evidence shows an inverse correlation between FOSL1 expression and the survival of patients with lung cancer and adenocarcinomas; however, its role in lung tumorigenesis remains elusive. In this work, we sought to determine the role of FOSL1 in Kras-induced lung adenocarcinoma in vivo and its downstream effector mechanisms. We used mice expressing the Kras oncogene in the lung with concomitant Fosl1 deletion, Kras-activated murine alveolar epithelial cells (mAECs) with Fosl1 deletion, and KRAS mutant human lung adenocarcinoma (HLAC) cells with FOSL1 deficiency, and performed cell proliferation and gene expression analyses. Mutant Kras induced Fosl1 expression in vitro (mAECs) and in vivo (lung tissue), and mice with Fosl1 deletion showed reduced levels of mutant Kras-induced lung tumorigenesis and survived longer than Fosl1-sufficient mice. Studies with mutant Kras-activated mAECs and KRAS-mutant HLAC cells revealed that FOSL1 regulates mutant KRAS-induced gene expression, thereby controlling cell proliferation and survival. In contrast, FOSL1 depletion in non-KRAS-mutant HLAC cells and nonmalignant human lung epithelia had no effect. Our data support the notion that FOSL1-mediated expression of amphiregulin and apoptotic and antioxidative genes plays a role in regulating HLAC cell proliferation and survival. FOSL1 is a determinant of lung cancer in vivo and regulates HLAC cell proliferation and survival, largely in the context of KRAS mutations. Activation of FOSL1 in adenocarcinomas may be a prognostic marker and potential target for human lung cancer with KRAS mutations.

Entities:  

Keywords:  AP-1; apoptosis; cyclins; epidermal growth factors; tumor cell growth

Mesh:

Substances:

Year:  2018        PMID: 29112457      PMCID: PMC5946328          DOI: 10.1165/rcmb.2017-0164OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   7.748


  29 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.

Authors:  Maria E Ramos-Nino; Cynthia R Timblin; Brooke T Mossman
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

3.  Expression of Fra-1 in human hepatocellular carcinoma and its prognostic significance.

Authors:  Xiao-Qiang Gao; Yong-Sheng Ge; Qing-Hua Shu; Hua-Xing Ma
Journal:  Tumour Biol       Date:  2017-06

Review 4.  Fos family members: regulation, structure and role in oncogenic transformation.

Authors:  E Tulchinsky
Journal:  Histol Histopathol       Date:  2000-07       Impact factor: 2.303

5.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility.

Authors:  Emmanuel Vial; Erik Sahai; Christopher J Marshall
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

6.  Multiple cis-elements mediate the transcriptional activation of human fra-1 by 12-O-tetradecanoylphorbol-13-acetate in bronchial epithelial cells.

Authors:  Pavan Adiseshaiah; Srinivas R Papaiahgari; Hue Vuong; Dhananjaya V Kalvakolanu; Sekhar P Reddy
Journal:  J Biol Chem       Date:  2003-09-17       Impact factor: 5.157

7.  Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins.

Authors:  G Risse-Hackl; J Adamkiewicz; A Wimmel; M Schuermann
Journal:  Oncogene       Date:  1998-06-11       Impact factor: 9.867

Review 8.  FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer.

Authors:  A S Dhillon; E Tulchinsky
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

9.  Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Authors:  Tristan Gallenne; Kenneth N Ross; Nils L Visser; Christophe J Desmet; Ben S Wittner; Lodewyk F A Wessels; Sridhar Ramaswamy; Daniel S Peeper
Journal:  Oncotarget       Date:  2017-03-15

10.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Authors:  Adrian Vallejo; Naiara Perurena; Elisabet Guruceaga; Pawel K Mazur; Susana Martinez-Canarias; Carolina Zandueta; Karmele Valencia; Andrea Arricibita; Dana Gwinn; Leanne C Sayles; Chen-Hua Chuang; Laura Guembe; Peter Bailey; David K Chang; Andrew Biankin; Mariano Ponz-Sarvise; Jesper B Andersen; Purvesh Khatri; Aline Bozec; E Alejandro Sweet-Cordero; Julien Sage; Fernando Lecanda; Silve Vicent
Journal:  Nat Commun       Date:  2017-02-21       Impact factor: 14.919

View more
  18 in total

Review 1.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

2.  A Pyroptosis-Related Signature Predicts Overall Survival and Immunotherapy Responses in Lung Adenocarcinoma.

Authors:  Kaibin Zhu; An Yan; Fucheng Zhou; Su Zhao; Jinfeng Ning; Lei Yao; Desi Shang; Lantao Chen
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

3.  Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling.

Authors:  Mohammad Mazharul Islam; Andrea Goertzen; Pankaj K Singh; Rajib Saha
Journal:  iScience       Date:  2022-05-30

4.  Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity.

Authors:  Preetish Kadur Lakshminarasimha Murthy; Rui Xi; Diana Arguijo; Jeffrey I Everitt; Dewran D Kocak; Yoshihiko Kobayashi; Aline Bozec; Silvestre Vicent; Shengli Ding; Gregory E Crawford; David Hsu; Purushothama Rao Tata; Timothy Reddy; Xiling Shen
Journal:  Dev Cell       Date:  2022-02-07       Impact factor: 13.417

5.  FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma.

Authors:  Li Li; Wenqi Zhang; Shanshan Zhao; Mao Sun
Journal:  Saudi J Gastroenterol       Date:  2019 Nov-Dec       Impact factor: 2.485

6.  Xanthohumol targets the ERK1/2‑Fra1 signaling axis to reduce cyclin D1 expression and inhibit non‑small cell lung cancer.

Authors:  Feng Gao; Ming Li; Li Zhou; Wenbin Liu; Huilan Zuo; Wei Li
Journal:  Oncol Rep       Date:  2020-07-20       Impact factor: 3.906

Review 7.  Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications.

Authors:  Precilla S Daisy; Kuduvalli S Shreyas; T S Anitha
Journal:  Mol Biotechnol       Date:  2021-01-01       Impact factor: 2.695

8.  Wnt Signaling Is Deranged in Asthmatic Bronchial Epithelium and Fibroblasts.

Authors:  Mahmood Yaseen Hachim; Noha Mousaad Elemam; Rakhee K Ramakrishnan; Khuloud Bajbouj; Ronald Olivenstein; Ibrahim Yaseen Hachim; Saba Al Heialy; Qutayba Hamid; Hauke Busch; Rifat Hamoudi
Journal:  Front Cell Dev Biol       Date:  2021-03-15

9.  Signature identification of relapse-related overall survival of early lung adenocarcinoma after radical surgery.

Authors:  Peng Han; Jiaqi Yue; Kangle Kong; Shan Hu; Peng Cao; Yu Deng; Fan Li; Bo Zhao
Journal:  PeerJ       Date:  2021-08-05       Impact factor: 2.984

10.  Fosl1 is vital to heart regeneration upon apex resection in adult Xenopus tropicalis.

Authors:  Hai-Yan Wu; Yi-Min Zhou; Zhu-Qin Liao; Jia-Wen Zhong; You-Bin Liu; Hui Zhao; Chi-Qian Liang; Rui-Jin Huang; Kyu-Sang Park; Shan-Shan Feng; Li Zheng; Dong-Qing Cai; Xu-Feng Qi
Journal:  NPJ Regen Med       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.